首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   94948篇
  免费   9555篇
  国内免费   5574篇
耳鼻咽喉   113篇
儿科学   4025篇
妇产科学   385篇
基础医学   7540篇
口腔科学   505篇
临床医学   8409篇
内科学   24232篇
皮肤病学   622篇
神经病学   1486篇
特种医学   3230篇
外国民族医学   20篇
外科学   24266篇
综合类   14965篇
现状与发展   31篇
一般理论   2篇
预防医学   2697篇
眼科学   1268篇
药学   6813篇
  38篇
中国医学   4525篇
肿瘤学   4905篇
  2024年   87篇
  2023年   1617篇
  2022年   1981篇
  2021年   3441篇
  2020年   3781篇
  2019年   3602篇
  2018年   3595篇
  2017年   3691篇
  2016年   4046篇
  2015年   3713篇
  2014年   6093篇
  2013年   6415篇
  2012年   5151篇
  2011年   6055篇
  2010年   5008篇
  2009年   4971篇
  2008年   5088篇
  2007年   5307篇
  2006年   5232篇
  2005年   4524篇
  2004年   3656篇
  2003年   3150篇
  2002年   2661篇
  2001年   2347篇
  2000年   1973篇
  1999年   1554篇
  1998年   1392篇
  1997年   1200篇
  1996年   1096篇
  1995年   978篇
  1994年   1028篇
  1993年   691篇
  1992年   787篇
  1991年   582篇
  1990年   473篇
  1989年   422篇
  1988年   403篇
  1987年   306篇
  1986年   258篇
  1985年   296篇
  1984年   243篇
  1983年   150篇
  1982年   187篇
  1981年   157篇
  1980年   129篇
  1979年   109篇
  1978年   109篇
  1977年   89篇
  1976年   100篇
  1975年   43篇
排序方式: 共有10000条查询结果,搜索用时 61 毫秒
61.
目的回顾性分析100例上海地区新型冠状病毒肺炎(简称"新冠肺炎")患者中西医结合治疗后的临床疗效及肝损伤情况。方法收集2020年1月22日至2020年2月10日上海市公共卫生临床中心收治的100例新冠肺炎患者的出入院临床资料及治疗方案信息,观察舌象、脉象、中医证候及肝损伤情况、临床结局与转归,比较临床症状、炎症及免疫相关指标的变化情况。结果①本研究中新冠肺炎患者的中医证型主要以热毒闭肺型、湿毒郁肺型、肺脾气虚型三型为主;实证明显偏多,虚证主要为肺脾气虚,气阴两虚偏少。②入院时无任何症状者有43例(占43.0%);服用中药汤剂以后,52例有症状患者的发热、咳嗽、咳痰、纳差、腹泻等主要症状均有不同程度改善。③中药汤剂治疗前与治疗1周后比较,患者的血清白细胞计数(WBC)、红细胞沉降率(ESR)、C反应蛋白(CRP)等炎症指标及CD4~+等免疫指标差异有统计学意义,均得到明显改善(P0.05)。④中药汤剂治疗前,共有16例患者已存在轻度肝损伤;将服中药治疗前及治疗1周后的肝功能指标进行比较,发现治疗后其中有2例患者的肝功能恢复正常,其余14例仍存在肝损伤、但均为轻度,且治疗前后肝功能各项指标差异无统计学意义(P0.05);其余84例患者在中药汤剂治疗前及治疗1周后肝功能各项指标均在正常范围内。⑤本研究中,共有81例(81.0%)患者病愈出院,19例(19.0%)患者仍在治疗中,病死率为0%。出院患者的平均住院时间为(16.0±5.8)d。5例重型患者中有3例病愈出院,剩余2例病情转轻,未向危重型发展,危重症转化率为0%。⑥81例出院患者中,仅有5例(6.2%)患者胸部CT提示肺炎感染病灶完全吸收,剩余76例(93.8%)患者胸部CT仍提示存在不同程度的异常病变。结论中西医结合治疗,特别是辨证应用中药汤剂治疗可明显减轻新冠肺炎患者的发热、咳嗽、纳差、腹泻等主要临床症状,改善体内炎症反应及免疫失调,降低病死率及危重症转化率,且不会造成药物性肝损伤。  相似文献   
62.
目的 探讨汉族、维吾尔族抗结核药物诱导的肝损伤(ATDLI)患者IL-10分泌量,比较两民族之间存在的差异。方法 选取新疆维吾尔自治区胸科医院、石河子大学医学院第一附属医院确诊的ATDLI患者。采用双抗体夹心ELISA测定患者IL-10的分泌量。比较两个民族以及两个民族不同性别、不同肝损伤程度的患者血清IL-10的表达量。结果 共收集ATDLI汉族组患者100例,维吾尔族组患者135例。维吾尔族组ATDLI患者IL-10分泌量[(56.30±17.24)pg/mL]高于汉族组[(45.81±11.04)pg/mL],差异有统计学意义(P<0.0001)。汉族轻度、中度及重度肝损伤组患者血清IL-10水平分别为(44.73±9.10)、(47.39±10.58)、(49.52±13.21)pg/mL;维吾尔族轻度、中度及重度肝损伤组患者血清IL-10水平分别为(52.30±15.24)、(56.84±13.71)、(58.62±14.38)pg/mL。组间比较显示,IL-10的分泌量汉族、维吾尔族中重度肝损伤组患者均高于轻度肝损伤组患者(均P<0.05)。结论 ATDLI患者IL-10分泌量随肝损伤程度的加重而升高。ATDLI患者IL-10分泌量维吾尔族高于汉族。  相似文献   
63.

Background

Refractory acute myeloid leukemia (AML) includes AML includes failure of disease to respond to standard induction chemotherapy, relapse within 6 months after first CR, and 2 or more relapses. The outcome of these patients is usually very poor; only a small proportion can be rescued by allogenic hematopoietic stem-cell transplantation (allo-HSCT). The aim of this study was to evaluate the efficacy and feasibility of allo-HSCT in patients with refractory AML.

Patients and Methods

We retrospectively analyzed the clinical outcome of 91 patients who were diagnosed with treatment-refractory AML at Hacettepe University Hospital between January 2002 and June 2018. Patients' disease status included refractory AML, defined as failure to respond to standard induction chemotherapy and relapse within 6 months after first complete remission.

Results

The median follow-up was 12 months (range, 0.5-184 months) for the entire group. Kaplan-Meier estimates of the 3-year overall survival for patients who underwent allo-HSCT and patients who received only salvage chemotherapy were 67% and 12%, respectively. Additionally, the Kaplan-Meier estimates of 5-year overall survival for patients who underwent allo-HSCT and patients who received only salvage chemotherapy were 44% and 4%, respectively (P < .001). Complete remission was obtained in 25 patients (83.3%) who underwent allo-HSCT; however, the disease of only 3 patients (3.8%) exhibited complete response after salvage chemotherapy.

Conclusion

Allo-HSCT is still the best-known treatment option with curative potential in patients with treatment-refractory AML. Therefore, all efforts should be made in an attempt to find a suitable matched donor in order to perform allo-HSCT.  相似文献   
64.
目的以肠道微生态为切入点探讨补肾化浊方联合粪菌移植治疗多囊卵巢综合征(PCOS)潜在机制。方法将30只6周龄SD大鼠随机分为空白组、模型组、中药组、粪菌移植组、中药+粪菌移植组,每组6只。来曲唑1 mg/(kg d)灌胃51 d,第22日起,中药组加灌补肾化浊方21.7 g/(kg d),粪菌移植组加灌新鲜粪便2 g/(kg d),中药+粪菌移植组加灌补肾化浊方21.7 g/(kg d)和新鲜粪便2 g/(kg d),连续30 d,另设空白组。干预结束后,腹主动脉取血检测大鼠血清性激素、空腹胰岛素(FINS)、空腹血糖(FPG),ELISA检测大鼠血清白细胞介素(IL)-18、肿瘤坏死因子-α(TNF-α)水平,HE染色观察大鼠卵巢形态学变化。结果与空白组比较,模型组大鼠卵巢呈多囊样改变,体质量、睾酮、黄体生成素(LH)/促卵泡激素(FSH)、FPG、HOMA-IR、IL-18、TNF-α水平均明显升高(P<0.01,P<0.001);与模型组比较,中药+粪菌移植组可显著改善上述指标(P<0.05,P<0.01,P<0.001),中药组可显著改善除TNF-α外各项指标(P<0.05,P<0.01),粪菌移植组可显著降低PCOS大鼠LH/FSH、IL-18水平(P<0.01,P<0.001);在降低IL-18水平方面,中药+粪菌移植组作用显著优于中药组(P<0.01)。结论中药联合粪菌移植可显著改善PCOS大鼠生殖和代谢功能,改善慢性炎症状态。  相似文献   
65.
Epidemiological studies on magnesium intake and primary liver cancer (PLC) are scarce, and no prospective studies have examined the associations of magnesium intake with PLC incidence and mortality. We sought to clarify whether higher magnesium intake from diet and supplements was associated with lower risks of PLC incidence and mortality in the US population. Magnesium intake from diet and supplements was evaluated through a food frequency questionnaire in a cohort of 104,025 participants. Cox regression was employed to calculate hazard ratios for PLC incidence and competing risk regression was employed to calculate subdistribution hazard ratios for PLC mortality. Restricted cubic spline regression was employed to test nonlinearity. We documented 116 PLC cases during 1,193,513.5 person-years of follow-up and 100 PLC deaths during 1,198,021.3 person-years of follow-up. Total (diet + supplements) magnesium intake was found to be inversely associated with risks of PLC incidence (hazard ratiotertile 3 vs. 1: 0.44; 95% confidence interval: 0.24, 0.80; ptrend = 0.0065) and mortality (subdistribution hazard ratiotertile 3 vs. 1: 0.37; 95% confidence interval: 0.19, 0.71; ptrend = 0.0008). Similar results were obtained for dietary magnesium intake. Nonlinear inverse dose–response associations with PLC incidence and mortality were observed for both total and dietary magnesium intakes (all pnonlinearity < 0.05). In summary, in the US population, a high magnesium intake is associated with decreased risks of PLC incidence and mortality in a nonlinear dose–response manner. These findings support that increasing the consumption of foods rich in magnesium may be beneficial in reducing PLC incidence and mortality.  相似文献   
66.
67.
ABSTRACT

Introduction

Hepatocellular carcinoma (HCC) is one of the most frequent tumors affecting the gastrointestinal tract and a universal cause of morbidity and mortality. Cabozantinib is a strong multi-inhibitor of receptor tyrosine kinases approved for renal cell carcinoma that could be useful also for the treatment of HCC.  相似文献   
68.
Graft-versus-host disease (GVHD) is the most common complication after allogeneic hematopoietic stem cell transplantation, and also an important factor affecting the survival and quality of life in patients after transplantation. Currently, immunosuppressive therapy is commonly used for GVHD, but the curative effect is not ideal. How to effectively prevent and treat GVHD is one of the difficulties to be solved urgently in the field of transplantation. In this paper, we summarize the latest progress in pathogenesis, prevention and treatment of GVHD with Chinese medicine(CM). We hope it will provide ideas and methods for exploring the mechanism and establishing a new comprehensive therapy for GVHD with CM.  相似文献   
69.
Multidrug resistance due to facilitated drug efflux mediated by ATP-binding cassette (ABC) transporters is a main cause for failure of cancer therapy. Genetic polymorphisms in ABC genes affect the disposition of chemotherapeutics and constitute important biomarkers for therapeutic response and toxicity. Here we correlated germline variability in ABC transporters with disease-specific survival (DSS) in 960 breast cancer (BRCA), 314 clear cell renal cell carcinoma and 325 hepatocellular carcinoma patients. We find that variant burden in ABCC1 is a strong predictor of DSS in BRCA patients, whereas candidate polymorphisms are not associated with DSS. This association is highly drug-specific for subgroups treated with the MRP1 substrates cyclophosphamide (log-rank p = 0.0011) and doxorubicin (log-rank p = 0.0088) independent of age and tumor stage, whereas no association was found in individuals treated with tamoxifen (log-rank p = 0.13). Structural mapping of significant variants revealed multiple variants at residues involved in protein stability, cofactor stabilization or substrate binding. Our results demonstrate that BRCA patients with high variant burden in ABCC1 are less prone to respond appropriately to pharmacological therapy with MRP1 substrates, thus incentivizing the consideration of genomic germline data for precision cancer medicine.  相似文献   
70.
目的:报道1例原发性肝淀粉样变病例,提高该病的认识水平,减少误诊误治。方法:分析我院2015年03月诊治并经病理学确诊的肝淀粉样变1例,并结合国内外文献,对本病的临床表现、诊断、治疗及预后进行讨论分析。结果:患者临床表现为右上腹隐痛、腹胀、肝大;既往:1年前因脾破裂于我院肝胆外科行脾切除术;术后病理:(脾)内有较多出血,有血肿形成,周围脾白髓萎缩,红髓间质有玻璃样变性,符合陈旧性脾破裂伴血肿形成。肝功提示:碱性磷酸酶明显升高,白蛋白减低,球蛋白升高,肝脏CT示肝脏体积明显增大,肝脏实质强化不均匀,胆囊结石。肝穿刺组织病理活检:肝细胞索变性坏死,有炎细胞浸润,肝索内肝细胞间有粉染无结构物质,免疫组化染色结果:CD34(-)、刚果红染色(+)。结论:对肝淀粉样变缺乏诊治经验是该病误诊的原因之一,以腹痛、肝大为主要临床表现极易误诊为脂肪肝,肝硬化及原发性肝癌。当临床上遇到肝脏肿大明显伴碱性磷酸酶明显升高且与其他肝功生化指标变化不平行时,尤其合并多器官受累表现者,须警惕肝淀粉样变的可能,确诊的惟一方法是肝穿刺行组织病理检查,但应注意出血等并发症。  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号